Elite Pharmaceuticals annual debt-to-equity ratio
2020
2021
2022
2023
2024
2025
2026
Elite Pharmaceuticals Debt-to-Equity Ratio Growth & History (ELTP)
Elite Pharmaceuticals's debt-to-equity ratio was 0.03 for fiscal 2026.
View full Elite Pharmaceuticals company overviewElite Pharmaceuticals annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | 0.03 | −0.04 | −58.58% |
| 2025 | 2025-03-31 | 0.07 | −0.00 | −6.02% |
| 2024 | 2024-03-31 | 0.07 | 0.07 | +96669.87% |
| 2023 | 2023-03-31 | 0.00 | −0.09 | −99.92% |
| 2022 | 2022-03-31 | 0.09 | −0.01 | −13.81% |
| 2021 | 2021-03-31 | 0.11 | −0.08 | −42.60% |
| 2020 | 2020-03-31 | 0.18 | — | — |
Elite Pharmaceuticals quarterly debt-to-equity ratio
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | 0.02 | −0.05 | −66.07% |
| Q4 2026 | 2026-03-31 | 0.03 | −0.04 | −58.58% |
| Q3 2026 | 2025-12-31 | 0.04 | −0.07 | −64.45% |
| Q2 2026 | 2025-09-30 | 0.05 | −0.03 | −37.46% |
| Q1 2026 | 2025-06-30 | 0.07 | 0.00 | +5.05% |
| Q4 2025 | 2025-03-31 | 0.07 | −0.00 | −6.02% |
| Q3 2025 | 2024-12-31 | 0.11 | 0.10 | +1745.70% |
| Q2 2025 | 2024-09-30 | 0.08 | 0.08 | +174224.86% |
| Q1 2025 | 2024-06-30 | 0.07 | 0.07 | +23921.44% |
| Q4 2024 | 2024-03-31 | 0.07 | 0.07 | +96669.87% |
| Q3 2024 | 2023-12-31 | 0.01 | 0.01 | +713.42% |
| Q2 2024 | 2023-09-30 | 0.00 | −0.00 | −95.21% |
| Q1 2024 | 2023-06-30 | 0.00 | −0.04 | −99.26% |
| Q4 2023 | 2023-03-31 | 0.00 | −0.09 | −99.92% |
| Q3 2023 | 2022-12-31 | 0.00 | −0.05 | −98.53% |
| Q2 2023 | 2022-09-30 | 0.00 | −0.06 | −98.21% |
| Q1 2023 | 2022-06-30 | 0.04 | −0.03 | −40.10% |
| Q4 2022 | 2022-03-31 | 0.09 | −0.01 | −13.81% |
| Q3 2022 | 2021-12-31 | 0.05 | 0.03 | +258.78% |
| Q2 2022 | 2021-09-30 | 0.06 | 0.04 | +199.80% |
| Q1 2022 | 2021-06-30 | 0.06 | −0.04 | −36.96% |
| Q4 2021 | 2021-03-31 | 0.11 | −0.08 | −42.60% |
| Q3 2021 | 2020-12-31 | 0.01 | −0.03 | −71.60% |
| Q2 2021 | 2020-09-30 | 0.02 | — | — |
| Q1 2021 | 2020-06-30 | 0.10 | — | — |
| Q4 2020 | 2020-03-31 | 0.18 | — | — |
| Q3 2020 | 2019-12-31 | 0.05 | — | — |
Elite Pharmaceuticals debt-to-equity ratio trends
Over the last five fiscal years, Elite Pharmaceuticals's debt-to-equity ratio decreased from 0.11 to 0.03, a change of −0.08. The latest reported quarter, Q1 2027, shows 0.02.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Elite Pharmaceuticals source filings ↗